CDTX INVESTOR ALERT: ROSEN, NATIONAL TRIAL LAWYERS,

NEW YORK, May 11, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation into potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) arising from allegations that Cidara Therapeutics may have provided materially misleading business information to the investing public has passed on.

SO WHAT: If you have purchased Cidara Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs under a contingency fee arrangement. Rosen Law Firm is preparing a class action lawsuit to recover investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=24442 or call Phillip Kim, Esq. at. Call us toll-free at 866-767-3653 or email [email protected] for class action information.

WHAT IS THIS ABOUT: On April 16, 2024, Cidara Therapeutics filed a Current Report on Form 8-K with the SEC. In that 8-K, Cidara Therapeutics disclosed that it “has previously issued audited consolidated financial statements for the fiscal years ended December 31, 2021 and 2022, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.” are included. and each of the Company’s previously issued unaudited condensed consolidated financial statements included in the Company’s quarterly reports on Form 10-Q for each of the quarterly periods in 2022 and 2023 (collectively, the “Previous Financial Statements”) should be filed with the (SEC). will no longer be considered reliable and should be reformulated(.)”

Cidara Therapeutics also announced that its management “concluded that the Company’s disclosure controls and procedures were not effective to the level of reasonable assurance and the Company’s internal control over financial reporting as of the end of each period covered by the restatement.” period was not effective.” ”

On this news, Cidara Therapeutics stock price fell $1.89 per share, or 11.46%, to close at $14.60 on April 16, 2024.

WHY ROSEN LAW: We encourage investors to select qualified advisors who have a track record of success in leadership roles. Companies issuing notices often do not have comparable experience, resources, or significant peer recognition. Many of these firms do not conduct securities class actions. Be wise when choosing your advisor. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest settlement ever in a securities class action lawsuit against a Chinese company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services in 2017 for number of securities class action settlements. The firm has been ranked in the top four every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named a Titan of Plaintiffs’ Bar by law360. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

For updates, follow us on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Lawyer advertising. Previous results do not guarantee a similar result.

—————–

Contact information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, PA
275 Madison Avenue, 40th floor
New York, NY 10016
Phone: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com